Exercise of Pre-funded Warrants by Reporting Persons in ESSA Pharma Inc.

On August 5, 2025, the Reporting Persons, including Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and Biotechnology Value Trading Fund OS LP, exercised pre-funded warrants to purchase 2,920,000 shares of ESSA Pharma Inc.'s common stock at $0.0001 per share. The exercise was conducted on a cashless basis, resulting in the issuance of 2,919,844 shares to the Reporting Persons after withholding 156 shares to cover the exercise price. The Reporting Persons, who are part of a Section 13(d) group, disclaim beneficial ownership of the securities except to the extent of their pecuniary interest. This transaction is significant as it reflects the Reporting Persons' continued investment in ESSA Pharma Inc.